Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IGF-I R


Brief Information

Name:Insulin-like growth factor I receptor
Target Synonym:IGF-I receptor,IGF1R,Insulin Like Growth Factor 1 Receptor,Insulin-Like Growth Factor 1 Receptor,Insulin-Like Growth Factor I Receptor,Soluble IGF1R Variant 1,Soluble IGF1R Variant 2,CD221 Antigen,CD221,IGFIR,JTK13,IGFR,Receptor, IGF Type 1,MGC18216
Number of Launched Drugs:6
Number of Drugs in Clinical Trials:26
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Synonym Name



The Insulin-like Growth Factor 1 Receptor (IGF1) is also known as CD221, JTK13. and is a transmembrane receptor that is activated by IGF-1 and by the related growth factor IGF-2. It belongs to the large class of tyrosine kinase receptors. This receptor mediates the effects of IGF-1, which is a polypeptide protein hormone similar in molecular structure to insulin. IGF1R is make up of two alpha subunits and two beta subunits ,the Both the α and β subunits are synthesized from a single mRNA precursor. The precursor is then glycosylated, proteolytically cleaved, and crosslinked by cysteine bonds to form a functional transmembrane αβ chain.The α chains are located extracellularly while the β subunit spans the membrane and are responsible for intracellular signal transduction upon ligand stimulation. IGF1R have a binding site for ATP, which is used to provide the phosphates for autophosphorylation. There is a 60% homology between IGF1R and the insulin receptor. In response to ligand binding, the α chains induce the tyrosine autophosphorylation of the β chains. This event triggers a cascade of intracellular signaling that, while somewhat cell type specific, often promotes cell survival and cell proliferation.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Mecasermin (Astellas/OrphanPacific) Approved Astellas Pharma Inc Somazon Japan Growth hormone deficiency; Dwarfism; Diabetes Mellitus, Lipoatrophic null 1994-10-05 HIV Infections; Diabetes Mellitus, Lipoatrophic; Heart Failure; Myocardial Infarction; Multiple Sclerosis; Lipodystrophy; Dwarfism; Growth hormone deficiency Details
Mecasermin (Ipsen) IGF-1; FK-780; MKN-031 Approved Ipsen Increlex United States Failure to Thrive Ipsen Inc 2005-08-30 Failure to Thrive; Autism Spectrum Disorder; X-Linked Combined Immunodeficiency Diseases; Phelan-McDermid syndrome; Growth Disorders; Muscular Dystrophy, Duchenne; Laron Syndrome Details
Brigatinib AP-26113 Approved Ariad Pharmaceuticals Inc Alunbrig, ALUNBRIG United States Carcinoma, Non-Small-Cell Lung Takeda Pharmaceuticals U.S.A. Inc 2017-04-28 Solid tumours; Ependymoma; Carcinoma; Neoplasms; Neurofibromatosis 2; Small Cell Lung Carcinoma; Myofibroma; Lymphoma, Large-Cell, Anaplastic; Brain metastases; Lung Neoplasms; Granuloma, Plasma Cell; Carcinoma, Non-Small-Cell Lung; Sarcoma, Kaposi; Neurilemmoma; Meningioma; Neuroma, Acoustic Details
IGF-1 (Biogen/Pharmacia & Upjohn) Approved Biogen Inc, Pharmacia & Upjohn Igef Sweden Dwarfism null 1994-01-01 Dwarfism Details
Ceritinib LDK-378; NVP-LDK378; NVP-LDK378-NX Approved Novartis Pharma Ag 赞可达, Zykadia EU Carcinoma, Non-Small-Cell Lung Novartis Europharm Ltd 2014-04-29 Colorectal Neoplasms; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Brain metastases; Esophageal adenocarcinoma; Granuloma, Plasma Cell; Lymphoma, Large-Cell, Anaplastic; Hematologic Neoplasms; Hepatic Insufficiency; Cholangiocarcinoma; Pancreatic Neoplasms; Thyroid Carcinoma, Anaplastic; Neoplasms; Glioblastoma; Stomach Neoplasms Details
Teprotumumab R-1507; RG-1507; RO-4858696; HZN-001 Approved Genmab A/S, F. Hoffmann-La Roche Ltd Tepezza United States Graves Ophthalmopathy Horizon Therapeutics Ireland 2020-01-21 Neoplasms; Graves Ophthalmopathy; Sarcoma; Breast Neoplasms; Diabetic macular oedema; Scleroderma, Diffuse; Carcinoma, Non-Small-Cell Lung Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Veligrotug ZB-001; VRDN-001; AVE-1642 Phase 3 Clinical Viridian Therapeutics Inc Solid tumours; Graves Ophthalmopathy; Multiple Myeloma; Breast Neoplasms Details
Teprotumumab biosimilar(Innovent) IBI-311 Phase 3 Clinical Innovent Biologics(Suzhou) Co Ltd Graves Ophthalmopathy Details
Ganitumab AMG-479 Phase 3 Clinical Amgen Inc Breast Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms; Lymphoma; Rhabdomyosarcoma, Alveolar; Lung Neoplasms; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Prostatic Neoplasms; Sarcoma; Sarcoma, Ewing; Bone metastases; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Colonic Neoplasms; Rectal Neoplasms; Carcinoid Tumor; Rhabdomyosarcoma, Embryonal; Ovarian Neoplasms; Rhabdomyosarcoma; Solid tumours; Intestinal Neoplasms Details
Linsitinib OSI-906; ASP-7487; OSI-906AA Phase 3 Clinical Astellas Pharma Inc, National Cancer Institute Multiple Myeloma; Paraganglioma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Orbital Diseases; Eye Diseases; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Exophthalmos; Breast Neoplasms; Prostatic Neoplasms; Sarcoma, Ewing; Adrenocortical Carcinoma; Thyroid Diseases; Graves Ophthalmopathy; Endocrine System Diseases; Skin Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Hashimoto Disease; Head and Neck Neoplasms; Ovarian Neoplasms; Carney Complex; Liver Neoplasms; Solid tumours; Chondrosarcoma Details
Conteltinib CT-707; SY-707 Phase 3 Clinical Shouyao Holding (Beijing) Co Ltd, Beijing Centaurus Biopharma Co Ltd Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
FPI-1434 [225Ac]-FPI-1434; FPX-01 Phase 2 Clinical Fusion Pharma Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Neoplasms; Adrenocortical Carcinoma; Uveal melanoma; Breast Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms Details
Dalotuzumab h7C-10; MK-0646; F-50-035 Phase 2 Clinical Pierre Fabre Group Solid tumours; Rectal Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Neuroendocrine Tumors; Multiple Myeloma; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung Details
CT-102 CT-102 Phase 2 Clinical Hangzhou Tianlong Pharmaceutical Co Ltd, Institute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences Liver Neoplasms; Carcinoma, Hepatocellular Details
lonigutamab ugodotin W-0101 Phase 2 Clinical Pierre Fabre Group Solid tumours Details
Mecasermin Rinfabate OHB-607; SHP-607; HGT-ROP-001; rhIGF-I/rhIGFBP-3; TAK-607 Phase 2 Clinical Insmed Noonan Syndrome; Failure to Thrive; Cerebral Intraventricular Hemorrhage; Bronchopulmonary Dysplasia; Myotonic Dystrophy; Retinopathy of Prematurity; Muscular Dystrophies; Laron Syndrome Details
MHB018A Phase 2 Clinical Minghui Pharmaceutical (Hangzhou) Co Ltd Graves Ophthalmopathy Details
Lonigutamab VB-421 Phase 2 Clinical Pierre Fabre Group Graves Ophthalmopathy Details
Cixutumumab A-12; IMC-A12; LY-3012217; NSC-742460 Phase 2 Clinical Eli Lilly And Company Gastrinoma; Adenocarcinoma, Bronchiolo-Alveolar; Gliosarcoma; Colorectal Neoplasms; Neuroblastoma; Medullary thyroid cancer (MTC); Chondrosarcoma, Extraskeletal Myxoid; Retinoblastoma; Neurofibrosarcoma; Brain Stem Neoplasms; Lymphoma, Mantle-Cell; Breast Neoplasms; Osteosarcoma; Prostatic Neoplasms; Sarcoma; Sarcoma, Ewing; Liposarcoma; Esophageal adenocarcinoma; Neuroectodermal Tumors, Primitive, Peripheral; Adenocarcinoma; Melanoma; Paraganglioma; Breast Neoplasms, Male; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Sarcoma, Alveolar Soft Part; Adrenocortical Carcinoma; Rhabdomyosarcoma, Alveolar; Carcinoma, Neuroendocrine; Glioma; Esophageal Squamous Cell Carcinoma; Hemangiopericytoma; Lung Neoplasms; Pinealoma; Rectal Neoplasms; Carcinoma, Merkel Cell; Stomach Neoplasms; Hemangiosarcoma; Insulinoma; Hepatoblastoma; Esophageal Neoplasms; Mesenchymoma; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma, Embryonal; Carcinoma; Fibrosarcoma; Kidney Neoplasms; Liver Neoplasms; Head and Nec Details
Picropodophyllin PPP; AXL-1717; NSC-36407 Phase 2 Clinical Axelar Ab Astrocytoma; Carcinoma, Non-Small-Cell Lung Details
NNC0268-0965 NNC0268-0965 Phase 1 Clinical Novo Nordisk A/S Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 Details
IGF-1 receptor oligodeoxynucleotide-based immunotherapy (Thomas Jefferson University) Phase 1 Clinical Sidney Kimmel Cancer Center Glioma Details
Insulin-Like Growth Factor 1 (Wright State Physicians) Phase 1 Clinical Wright State Physicians Nasolabial fold wrinkles; Burns; Sunburn Details
SAR-446159 ABL-301; SAR-446159 Phase 1 Clinical Abl Bio Inc Parkinson Disease Details
VRDN-003 VRDN-003 Phase 1 Clinical Viridian Therapeutics Inc Graves Ophthalmopathy Details
VRDN-002 VRDN-002 Phase 1 Clinical Viridian Therapeutics Inc Graves Ophthalmopathy Details
LX-101 (Lirum Therapeutics) 765IGF-MTX; IGF/MTX Phase 1 Clinical Lirum Therapeutics Inc Head and Neck Neoplasms; Anemia, Refractory, with Excess of Blasts; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Neoplasms; Graves Ophthalmopathy; Breast Neoplasms; Brain Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Melanoma; Gastrointestinal Neoplasms Details
ZB-011 ZB-011; ZB011 Phase 1 Clinical Viridian Therapeutics Inc Graves Ophthalmopathy Details
Teprotumumab(Zhejiang Boxiao Bio-pharma) Phase 1 Clinical Zhejiang Boxiao Bio-pharmaceutical Co Ltd Graves Ophthalmopathy Details
PHP-1003 PHP-1003; PHP1003 Phase 1 Clinical Suzhou Pulekang Pharmaceutical Technology Co Ltd Graves Ophthalmopathy Details
124I-CPD-1023-figitumumab 124I-CPD-1028; 125I-CPD-1028; CPD-1028-[124I]; CPD-1028-[125I]; FPX-1028 Phase 1 Clinical Fusion Pharma Neoplasms Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message